ClinicalIntelPulse · Clinical Global Trials

import { wrapFetchWithPayment } from "@x402/fetch";
import { privateKeyToAccount } from "viem/accounts";

const account = privateKeyToAccount(process.env.PRIVATE_KEY);
const fetchWithPay = wrapFetchWithPayment(fetch, account);

const res = await fetchWithPay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials", {
  method: "GET",
});
const data = await res.json();

curl -X GET \
  "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials?condition=Disease+%E2%80%94+e.g.+%22Malaria%22+%7C+%22Tuberculosis%22+%7C+%22Dengue%22+%7C+%22Sickle+Cell+Disease%22+%7C+%22Chagas+Disease%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&region=global+%7C+africa+%7C+asia+%7C+europe+%7C+latin-america+%7C+middle-east+%7C+north-america+%28default%3A+global%29" \
  -H "X-PAYMENT: <signed x402 payment>"

{
  "development_finance_context": "GAVI, Global Fund, UNITAID, PMI, USAID funding dominant. Wellcome Trust largest private funder.",
  "global_registries_coverage": {
    "anzctr_australia": "5 trials — malaria research centers in Melbourne (Burnet Institute)",
    "chictr_china": "Limited malaria — primarily domestic infectious disease",
    "clinical_trials_eu": "12 EU-registered trials",
    "ctri_india": "18 trials — India significant manufacturer (Serum Institute)"
  },
  "global_trial_distribution": {
    "clinicaltrials_gov_count": 312,
    "estimated_non_us_registries": "200+ additional trials in WHO ICTRP member registries",
    "geographic_concentration": "Sub-Saharan Africa dominates — 68% of all active malaria trials",
    "most_active_countries": [
      "Kenya (45 trials)",
      "Uganda (38)",
      "Burkina Faso (31)",
      "Mali (28)",
      "Tanzania (24)",
      "United States (22)",
      "Thailand (19)"
    ]
  },
  "opportunity_assessment": "R21 scale-up is the near-term priority. Resistance crisis in SE Asia creates urgent Phase 3 need for alternative regimens.",
  "phase3_highlights": [
    {
      "countries": [
        "Burkina Faso",
        "Kenya",
        "Mali",
        "Tanzania"
      ],
      "drug": "R21/Matrix-M",
      "notes": "WHO prequalification received 2023. First malaria vaccine with >75% efficacy in high-transmission settings.",
      "sponsor": "Serum Institute / Oxford"
    }
  ],
  "query_summary": {
    "condition": "Malaria",
    "region": "global"
  },
  "regulatory_landscape": {
    "ema": "Article 58 mechanism for non-EU disease burden assessments. R21 assessed via UK MHRA.",
    "fda": "Limited footprint — malaria not a US priority market; few NDA filings",
    "nmpa_china": "Artemisinin derivatives approved; combination therapies standardized under WHO guidelines",
    "who_prequalification": "Primary pathway for SSA deployment. RTS,S and R21 both WHO-prequalified."
  },
  "unmet_needs_by_region": {
    "latin_america": "Vivax malaria (neglected vs. falciparum)",
    "southeast_asia": "Artemisinin resistance (Pfkrelch mutations) — urgent — treatment of resistant falciparum",
    "sub_saharan_africa": "Pediatric dosing, pregnancy, severe malaria, transmission blocking"
  }
}